HC Wainwright Comments on Cassava Sciences, Inc.'s FY2025 Earnings (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) - Research analysts at HC Wainwright issued their FY2025 earnings per share estimates for Cassava Sciences in a note issued to investors on Tuesday, October 8th. HC Wainwright analyst V. Bernardino forecasts that the company will post earnings of ($1.75) per share for the year. HC Wainwright currently has a "Buy" rating and a $116.00 target price on the stock. The consensus estimate for Cassava Sciences' current full-year earnings is ($5.70) per share.

Separately, Rodman & Renshaw restated a "buy" rating and set a $107.00 price objective on shares of Cassava Sciences in a research report on Thursday, August 8th.

Cassava Sciences Trading Down 0.6 %

SAVA stock traded down $0.14 on Thursday, hitting $24.86. The company had a trading volume of 1,767,286 shares, compared to its average volume of 1,747,773. Cassava Sciences has a 12-month low of $8.79 and a 12-month high of $42.20. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -11.47 and a beta of -0.63. The stock's 50-day simple moving average is $28.19 and its 200 day simple moving average is $22.15.

Cassava Sciences (NASDAQ:SAVA - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.44) by $0.57. During the same quarter in the prior year, the business earned ($0.63) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. EntryPoint Capital LLC boosted its stake in Cassava Sciences by 1,251.2% during the first quarter. EntryPoint Capital LLC now owns 2,297 shares of the company's stock worth $47,000 after buying an additional 2,127 shares during the period. Dark Forest Capital Management LP purchased a new stake in Cassava Sciences in the 2nd quarter valued at $131,000. Arizona State Retirement System increased its position in Cassava Sciences by 4.2% in the 2nd quarter. Arizona State Retirement System now owns 11,495 shares of the company's stock valued at $142,000 after acquiring an additional 468 shares during the period. NBC Securities Inc. lifted its holdings in shares of Cassava Sciences by 9.3% during the first quarter. NBC Securities Inc. now owns 7,650 shares of the company's stock worth $155,000 after purchasing an additional 650 shares during the period. Finally, Profund Advisors LLC lifted its position in Cassava Sciences by 4.6% in the second quarter. Profund Advisors LLC now owns 13,440 shares of the company's stock valued at $166,000 after purchasing an additional 591 shares during the period. Hedge funds and other institutional investors own 38.05% of the company's stock.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.